The tweet was deleted by the author.
But we saved everything 🙂.
Atossa Therapeutics, Inc. announced the publication of pivotal results from its KARISMA-Endoxifen trial, reporting significant reductions in mammographic breast density among healthy premenopausal women.
The findings bolster the case for the continued development of (Z)-endoxifen as a preventive option for breast cancer. Atossa Therapeutics is advancing its research towards addressing unmet needs in breast cancer prevention, signaling a potentially important development in women’s health.
Atossa previously advanced Z-endoxifen in oncology with new U.S. FDA designations and changes in clinical leadership, according to a recent update. The company has also discussed endoxifen as a novel approach for Duchenne muscular dystrophy in a podcast presentation. These developments reflect the company’s expanding pipeline across therapeutic areas.